To add new insight to our previous work on molecular epidemiology of Bordetella pertussis in Argentina, 57 clinical isolates obtained during two periods, 1969-1989 and 1997-2006, were analyzed in their prn and ptxS1 gene sequences and pulsed-field gel electrophoresis profiles (PFGE). Non-vaccine type ptxS1A was detected in isolates obtained since 1969. From 1989 a shift of vaccine prn1 type to non-vaccine prn2 type predominance was observed. This was also reflected in a transition of PFGE group IV to group VI. These results show that non-vaccine B. pertussis strains are circulating nowadays. To analyze whether the observed genomic divergences between vaccine strains and clinical isolates have functional implications, protection assays using the intranasal mouse challenge model were performed. For such experiments, the clinical isolate Bp 106 was selected as representative of circulating bacteria since it became from the major group of the PFGE dendrogram (PFGE group VI). Groups of mice were immunized either with whole-cell DTP vaccine (ptxS1B/prn1) or a vaccine prepared by us containing Bp 106. Immunized mice were then challenged with B. pertussis vaccine strain (Tohama harboring ptxS1B/prn1) or the clinical isolate Bp 106 (ptxS1A/prn2).
Introduction
Pertussis is an infectious respiratory disease caused by the bacterium Bordetella pertussis, an exclusively human pathogen. This disease, though preventable by vaccination, remains one of the top ten causes of death worldwide in childhood. Moreover, in countries with highly vaccinated populations a pertussis resurgence was reported (2, 12, 13, 19, 36, 40, 43, 50) . Several explanations have been suggested for this resurgence in such populations: low efficacy of the used vaccine, waning immunity in the absence of both natural and vaccinal boosters after 18 months of age, and adaptation of the B. pertussis circulating population (24, 27, 31, 39, 41, 46, 51) . One explanation is based on studies of B. pertussis strains from
The Netherlands first and then other countries that focused on genomic analysis by pulse field gel electrophoresis (PFGE) and on sequences of the genes that code for two immunogens, pertactin (prn) and S1 subunit of pertussis toxin (ptxS1) (8, 19, 21, 26, 37, 40, 41) . Data from these studies have been interpreted to suggest that vaccination selects for strains that have different genotypes from those used to make the vaccine, allowing the spread of escape mutants (15, 34, 40) . This vaccine-driven antigenic evasion seems not to be exclusive for pertussis since a growing body of evidence is pointing this for at least three other diseases: Hepatitis B virus, Streptococcus pneumoniae, and Haemophilus influenzae (5, 7, 10, 11, 44, 47, 48) .
In Argentina, during last years an increase in pertussis incidence was registered by Public Health Ministry, even before improvements on diagnostic methodology were introduced. In this country whole cell pertussis vaccine was introduced in the 1960s and is still the only kind of pertussis vaccine being used. Since 1985 the vaccination schedule is 2, 4, 6 and 18 months with a school entry booster at 5-6 years of age. Molecular characterization of B. pertussis isolates (n=28) obtained in Argentina during 1997-2003 was done (19) . The isolates appeared to be genotypically different from the vaccine strain in use. The isolates were comprised of ptxS1A (100%), and prn2 (93%) or prn1/7 (7%) variants. These
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on August 27, 2017 by guest http://cvi.asm.org/ Downloaded from allelic variants are different from those present in the vaccine strain (ptxS1B/D prn1) but identical to those found in European and North American countries.
Though more epidemiological and molecular data should be collected in order to describe more precisely the pertussis disease scenario, it is clear that the control of pertussis requires an improvement. Currently used pertussis vaccines in many countries are based on strains or proteins obtained from strains isolated before 1957, which are different from the current circulating bacteria.
Thus, novel proteins from contemporary isolates should be considered in the design of new acellular vaccines. Surface proteins play a fundamental role in the interaction between the bacterial cell and its environment; hence, these bacterial constituents may become components of such vaccines. Comparison of multiple exposed proteins in B. pertussis strains used at present in vaccine production against contemporary circulating strains may allow the identification of new immunogens that can be incorporated in a new broadly protective vaccine.
In this study, for the first time a procedure that allows the identification of surface accessible proteins in B. pertussis was described. This methodology was applied to compare enriched membrane samples obtained from well known laboratory-adapted B. pertussis strains widely used for vaccine production, and a B. pertussis local isolate. The results obtained revealed that genomic divergence that seems to have a role in pertussis protection as here demonstrated using the accepted animal model, could be extended to the bacterial surface proteome. Thus, this new insight on proteins located at the surface of B. pertussis strains may assist in the identification of potential vaccine candidates. Overall, this manuscript presents an attractive approach for comparison of the surface of Bordetella strains, and provides a framework for future proteomic analyses. Ages of patients ranged from 1 month to 5 years with the median age being 4 months. Thirty three patients from whom bacteria was isolated were aged less than 18 months and only one aged 5 years old.
For the other positive culture patients no data on age were reported.
PCR, sequencing and PFGE. PCR, sequencing, and PFGE were performed according to standardized recommendations for B. pertussis typing (38). Bacteria were cultivated on Bordet Gengou medium containing defibrinated sheep blood at 36°C for 72 h. For PFGE, B. pertussis strains 134 (USA), 509 (The Netherlands, Mexico), 10536 , Tohama (Japan), and 18323 (USA) were used as reference strains.
Briefly, DNA sequencing of relevant regions of the prn and ptxS1 genes was performed on PCR fragments as described by Mooi et al. (38) . For sequencing of region 1 the primer pair AF/AR (5'-CAATGTCACGGTCCAA-3'/5'-GCAAGGTGATCGACAGGG-3') was used, and for sequencing of region 2 the primer pair BF/BR (5'-AGCTGGGCGGTTCAAGGT-3'/5'-CCGGATTCAGGCGCAACTC-3') was used. For pertussis toxin, primers S1-F2 (5'-CCCCTGCCATGGTGTGATC-3') and S1-R2 (5'-AGAGCGTCTTGCGGTCGATC-3') were used to amplify a 930 Bp product, which contains the complete ptxS1 gene. The S1-F2/S1-R2 were also used for sequencing (18). Mutations were confirmed by sequencing using two additional primers S1-MF/S1-MR (5'-ACAATGCCGGCCGTATCCTC-3'/5'-TTCGAAGTACGAGCTGGCGG-3'). Gels were stained for 40 minutes in 500 ml deionized water containing 50 µl of a 10 mg/ml solution of ethidium bromide. Unbound ethidium bromide was removed by washing gels in deionized water for 60 minutes. DNA fragments were visualized on a UV transilluminator, and gels were photographed with a Gel Doc 2000 system.
Tohama strain was used in each gel as external quality control, to assess whether the reproducibility of its banding pattern was consistent with previously published ones, and between runs.
BioNumerics (Applied Maths Sint-Martens-Latem, Belgium) 3.5 version software was used to normalize the DNA fragment migration distances relative to those of the Salmonella braenderup strain H9812.
DNA fragments were analyzed with at least one band discrepancy as the basis for discriminating among profiles.
The unweighted pair group method using arithmetic averages (UPGMA) was used as the clustering method, with a 1% band tolerance and 1% optimization settings with the Dice coefficient. At different times post inoculation, three mice from each group were sacrificed and the lungs were removed aseptically. Lungs were homogenized in PBS, and appropriate dilutions were plated onto BGA to determine the number of viable bacteria present in the lungs. All the experiments were performed two times, and they gave consistent results. The lungs of infected animals were aseptically removed, homogenized in the sterile PBS, serially diluted, and then plated on Bordet-Gengou plates to determine bacterial recoveries at different time points during the course of infection. The outcome of the challenge was followed by performing CFU counts on lung homogenates from individual mouse.
All the experiments were performed three times, and they gave consistent results. The purpose of the conditioning step (500 V for 30 min) was to remove salt ions and charged contaminants, and this was followed by linear voltage ramping for 30 min at 1,000 V. In the final focusing step, the maximum voltage of the ramp step was maintained (up to 5,000 V h), and the current did not exceed 50 µA/strip. After IEF, the strips were equilibrated in 50 mM In this study we used PFGE and prn and ptxS1 typing to add new insight in the characterization of B.
pertussis isolates obtained in Argentina in two periods: 1969-1989 and 1997-2006.
Since it was previously reported that PFGE analysis with XbaI gave optimal discrimination (1, 28), we used this enzyme to classify the vaccine strains and local isolates into PFGE profile groups. Figure 1 shows the dendrogram of DNA profiles relatedness calculated by UPGMA clustering of Dice coefficients. A total of 39 distinct PFGE profiles named V1-V3 for vaccine strains, R1 for reference strain and A1-A35 for clinical isolates were observed. These profiles were classified into six major groups (I-VI) based on a criterion of similarity higher than 0.70. The three groups corresponding to the vaccine (Fig 1) .
This lower than expected level of B. pertussis population diversity may be a consequence of sequential bottlenecks or fitness differences between the strains that favor only those variants able to evade the immunity induced by vaccination or with increased virulence. That is, circulating bacteria could have overcome the strong bottleneck of the immunity induced by vaccine strain by accumulating mutations that allowed them to evade host responses. Differences between circulating bacteria and vaccine strains were also observed when the sequences of ptxS1
and prn alleles (38) were analyzed. Studies on ptxS1 subunit polymorphism showed that 53 B. pertussis isolates contained the ptxS1A allele and only 4 had ptxS1-no-A. By contrast, the vaccine strains used in this country contain ptxS1B/D alleles. For pertactin, a significant correlation was observed between the PFGE groups and prn alleles. All of the 11 isolates from group IV contained the prn1 and all isolates from group VI had prn2 alleles. It seems that prn2 have replaced the prn1 present in old isolates.
In the United Kingdom and Finland a change from prn1 to prn2 was already observed in isolates from 1982, in the Netherlands from 1990 and in Taiwan from 1997 (16, 21, 36, 41). These same variations seem to support a possible explanation that the impact of the immune responses induced by vaccination that has been recorded to these epitopes was strong enough to structure the population into discrete with PBS. Two hours later and at days 5 and 8 after the challenge, the lungs were collected for bacterial count. As expected, significant differences between immunized animals and the control group were observed (p < 0.001, Table 1 ). Adequate elimination rates were observed in mice immunized and challenged with the same kind of strain (immunization and challenge with vaccine strain). However, a lower potential of protective immunity induced by whole-cell vaccination in elimination rates of the clinical B. pertussis isolate Bp 106 (prn2/ptxS1A) from the lungs was observed, compared to vaccine strain Tohama (prn1/ptxS1B) (p < 0.001, Table 1 ). Furthermore, when mice were immunized with a vaccine containing a clinical isolate and challenged with vaccine strain or antigenic divergent clinical isolates, lower clearance efficiency for vaccine strain was induced (p < 0.002) already at day 5 after challenge (Table 1) .
These results could not be attributed to differences in colonization ability between vaccine strain or clinical isolate since the number of colonies recovered at each time in infection experiments for both strains were the same (not shown)
Overall, these results clearly demonstrate that the efficacy of whole cell vaccines depends on the relatedness between the vaccine strain and the circulating ones. In addition, the present observations support the hypothesis of the role of divergence of circulating strains in pertussis resurgence. (Table 2) . From this last group, some of the proteins such as EF-Tu, ET TS, enolase, 60-kDa chaperonin and some dehydrogenases may be associated to membranes as was observed in Neisseria meningitidis (17).
Some of the proteins separated by 2D electrophoresis were present as multiple spots exhibiting variability in pI values (horizontal spot patterns) (Fig 2) . Charge variants included EF-Tu, 60-kDa chaperonin, outer membrane porin protein precursor, serum resistance protein, and serine protease. These may represent natural isoforms or an artifact caused by sample preparation or two-dimensional electrophoresis.
Similarly, serum resistance protein resolved in multiple spots of differing masses and pIs, suggesting possible protein processing, degradation, and/or modifications (Fig 2) .
Few proteins could be detected as differential among the three analyzed vaccine strains. Though most of those identified proteins in Bp 106 would be involved in carbohydrate metabolism, some of them were recently described in other Gram-negative bacteria as having roles in pathogenicity (14) and immunogenicity (33).
One of these enzymes is the dihydrolipoamide deshydrogenase (Lpd) which is an essential functional subunit of the multienzyme piruvate deshydrogenase complex (PDHC), with a predicted molecular mass of 50.37 kDa. PDHC is comprised of multiple copies of the ternary complex of Lpd, dihydrolipoamide transacetylase, and pyruvate dehydrogenase enzymes and is involved in the oxidation of pyruvate. The dihydrolipoamide dehydrogenase enzyme allows the continued function of the pathway by maintaining the correct redox state of the enzymes involved in the bioconversion. For Mycobacterium it was described that the Lpd has an important role in host colonization and pathogenesis and in Haemophilus influenzae type B, a transposon insertion in lpdA -dihydrolipoamide dehydrogenase gene homolog-convert the virulent bacteria in attenuated bacteria. When the H. influenzae LpdA mutant was used to challenge 5day-old infant rats intraperitoneally, it was unrecoverable compared to the wild-type recovery rate (29).
These evidences point out that the Lpd identified in Bp 106 may have a role in pathogenicity that needs to be investigated.
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In Bp 106 two other differential spots were detected: polysaccharide biosynthesis protein (spot 41
Bp3150) and capsular polysaccharide biosynthesis protein (spot 42 Bp1630). Since capsules are often key contributors to the ability of pathogens to withstand host defense mechanisms (42), the expression of these proteins in Bp 106 may be a consequence of its necessity to evade the host immune response induced by vaccination. A locus that is likely to encode a type II polysaccharide capsule (20) comprising three regions that are involved in export/modification, biosynthesis and transport was previously reported to be present in the Bordetella genome sequence (45). In B. pertussis Tohama strain, it was reported that the central part of the locus is intact, but the 3′ region of one gene has undergone an inversion event and at the 5′ end of the locus, an IS-element-mediated rearrangement has deleted part of region 1 (which contains genes that are involved in export/modification) and moved two of these export genes to a different part of the chromosome. It will be interesting to analyze the structure of this locus in Bp 106.
This study not only shows that the previously observed genomic divergences between Argentinean B.
pertussis circulating population and vaccine strains is registered nowadays but, more importantly, that these genomic differences have implications in pertussis protection and also could be extended to the protein expression patterns. Table 2 . 
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